Sm04554

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • Tenma
    replied
    Has anyone seen this trial about SM? https://www.anzctr.org.au/Trial/Regi...aspx?id=368801
    Wow thats great news!

    Now they are running 3 trials.

    Btw, I don’t know if it was mentioned before but found info from april about samumed expanding their facilities and obtaining a good reduction in taxes:

    San Diego County Home Sales Climb Sharply in March Home Prices Also Rise Homes sold in San Diego County in March increased sharply month over month from


    “…Samumed LLC of San Diego, a biopharmaceutical research and development firm that will create 273 jobs by investing $30.5 million, for which it will receive a $2.1 million tax credit.”

    One thing is for sure, they are investing heavily and have high hopes for this drug.

    Leave a comment:


  • lacazette
    replied
    lacazette aswell

    Leave a comment:


  • JayM
    replied
    Hey man no worries. What's your name on ***? I will send you a message

    Leave a comment:


  • lacazette
    replied
    Hey Jaym, I tried the other day as you asked to contact you on ***, but they don't allow me to access to your profile and send a msg. and still not today dude

    Leave a comment:


  • JayM
    replied
    Guy's we have already been though all of this like 20 pages back.

    Leave a comment:


  • unbalding
    replied
    Originally posted by Justinian
    It's gotta be either what you said, or in anticipation of the 21st century cures act which allows the use of biomarkers to speed the approval process.
    That's a great point, I hadn't thought of that. Hopefully you're right.

    Leave a comment:


  • baldybald
    replied
    Now the problem is that we do not know what it contains so we can use it on ourselves, like setipiprant

    Leave a comment:


  • Justinian
    replied
    Originally posted by unbalding
    It seems to me it's probably working, but not as well as they had hoped. They want more information to modify it to improve efficacy. They must be getting pretty decent results though to even bother with that.
    It's gotta be either what you said, or in anticipation of the 21st century cures act which allows the use of biomarkers to speed the approval process.

    Leave a comment:


  • unbalding
    replied
    Originally posted by champpy
    the way I'm reading this purpose portion of the clinical trial is that they're trying to understand exactly how this is working... Which may mean that it actually is working. this may be a good sign
    It seems to me it's probably working, but not as well as they had hoped. They want more information to modify it to improve efficacy. They must be getting pretty decent results though to even bother with that.

    Leave a comment:


  • Tenma
    replied
    Originally posted by champpy
    the way I'm reading this purpose portion of the clinical trial is that they're trying to understand exactly how this is working... Which may mean that it actually is working. this may be a good sign
    Agreed. No way they would waste money funding another trial if the stuff is performing poorly.

    What intrigues me is how effective is SM.

    Leave a comment:


  • champpy
    replied
    the way I'm reading this purpose portion of the clinical trial is that they're trying to understand exactly how this is working... Which may mean that it actually is working. this may be a good sign

    Leave a comment:


  • Hairmore
    replied
    I cannot open the link. Seems like they closed the recruiting since yesterday or there are just to many who were still wanted to participate very badly.

    Leave a comment:


  • unbalding
    replied
    If anyone is in Texas, Ohio, Virginia, or Michigan, they are still recruiting participants.

    Leave a comment:


  • Seuxin
    replied
    I really would like to know too the timeline of this SM !

    Leave a comment:


  • candu2015
    replied
    Originally posted by lacazette
    Hey good find thanks Candu . The first ever trial of SM was in australia, they have facilities there
    that new micro trial is interesting, it adds some safety biomarkers and seems they had choose a define protocol

    Daily topical application of 0.25% (w/v) solution of SM04554 to scalp for 14 days.
    SM04554 is supplied as in a non-aqueous solution of PEG400 at concentration of 0.25% weight per volume (w/v);1 vial of 0.5mL
    Subject will apply at least 0.3mL of a 0.5mL study drug (SM04554) at site during visits under supervision of site staff.


    Primary outcome
    To characterise pharmacokinetics of topically applied 0.25% SM04554 solution to male subjects with androgenetic alopecia, estimated using available concentration-time data for Cmax, tmax, AUC (0-24), AUC (0-infinite time) and t(1/2) from collected blood samples.
    Timepoint
    On treatment days 1 and 14 blood samples will be taken prior to study drug application and at 1, 2, 4, 6, 12 and 24 hours post study drug application.

    On treatment days 5 and 10 blood samples will be taken prior to study drug application only.
    Secondary outcome
    To characterise safety and tolerability of topical SM04554 0.25% solution to scalp of male subjects with androgenetic alopecia as determined by changes from baseline in vital signs, clinical laboratory parameters and electrocardiography(ECG)
    Timepoint
    ECG: days 1 and 14 prior and 4 hour post study treatment
    Vital signs: screening day, days 1, to 14 prior to study treatment, on days 1 and 14 at 4 and 12 hours post study treatment. ECG also performed at follow up visit day 15.
    Clinical chemistry, haematology parameters and urinalysis: screening day and day 14 prior to study treatment and day 15 post study treatment
    Secondary outcome
    To characterise safety and tolerability of topical SM04554 0.25% solution to scalp of male subjects with androgenetic alopecia as determined by adverse events (such as skin irritation (erythema,scaling puritis, stinging) , eye irritation) and assessed by medically qualified study staff.
    Timepoint
    Every day from first day study drug application to day 14 and at end of study day 15.
    Secondary outcome
    To characterise safety and tolerability of topical SM04554 0.25% solution to scalp of male subjects with androgenetic alopecia as determined by investigator skin assessment of the scalp and hands.
    I follow with great interest this product, it's a different approach.
    I am very hopeful that this treatment will come soon.
    It seems they already have chosen the 0.25%?
    What do you think?
    I'm sorry for my English

    Leave a comment:

Working...